BRIEF-Prothena Announces Phase 3 Affirm-Al Clinical Trial For Birtamimab In Patients With Al Amyloidosis Did Not Meet Primary Endpoint

Reuters
24 May
BRIEF-Prothena Announces Phase 3 Affirm-Al Clinical Trial For Birtamimab In Patients With Al Amyloidosis Did Not Meet Primary Endpoint

Prothena Corporation PLC PRTA.O:

  • PROTHENA ANNOUNCES PHASE 3 AFFIRM-AL CLINICAL TRIAL FOR BIRTAMIMAB IN PATIENTS WITH AL AMYLOIDOSIS DID NOT MEET PRIMARY ENDPOINT

  • PROTHENA CORPORATION PLC - TO DISCONTINUE BIRTAMIMAB DEVELOPMENT

  • PROTHENA CORPORATION PLC - PHASE 3 AFFIRM-AL TRIAL DID NOT MEET PRIMARY ENDPOINT

  • PROTHENA CORPORATION PLC - SECONDARY ENDPOINTS NOT MET IN AFFIRM-AL TRIAL

  • PROTHENA CORPORATION PLC - BIRTAMIMAB GENERALLY SAFE AND WELL-TOLERATED

  • PROTHENA CORPORATION PLC - BOARD TO DECREASE SPEND, EXPECTS WORKFORCE REDUCTION

Source text: ID:nBw3582YBa

Further company coverage: PRTA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10